In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drug…
With corporate earnings season in full swing — watch for McDonalds, along with Catepillar, Amazon and other — and with the Fed meeting on interest rates, the GDP estimate and housing numbers coming out — the week ahead is ex…
Wall Street’s consensus sees the S&P 500 tacking on an 11% gain over the next 12 months — with lots of ups and downs along the way. That has us inclined to play defense, with an eye toward bargain stocks paying generous, susta…
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the…
With interest rates so low and corporations sitting on $2 trillion in cash, a slew of mergers and takeovers across a number of industries appears likely in 2011. But picking individual companies is awfully tough. Here’s a bette…